MEIP MEI Pharma Inc.

3.65
+0.35  (+11%)
Previous Close 3.3
Open 3.79
Price To Book 5.22
Market Cap 387,425,164
Shares 105,998,677
Volume 5,282,541
Short Ratio
Av. Daily Volume 2,439,948
Stock charts supplied by TradingView

NewsSee all news

  1. MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program

    SAN DIEGO, May 26, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will host an investor and

  2. MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress

    SAN DIEGO and TOKYO, May 14, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a

  3. Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes

    LUGANO, Switzerland and SAN DIEGO, May 13, 2020 /PRNewswire/ -- Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, and MEI Pharma, Inc. (NASDAQ:MEIP), a

  4. MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b Study Evaluating ME-401 on an Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies; Data to be Featured in the American Society of Clinical Oncology 2020 Virtual Scientific Program

    SAN DIEGO and TOKYO, May 13, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:

  5. MEI Pharma Reports Fiscal Third-Quarter 2020 Results and Recent Corporate Highlights

    SAN DIEGO, May 7, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its third quarter ended

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data presented at ASCO May 29, 2020.
Pracinostat in combination with Vidaza
High-risk Myelodysplastic Syndrome (MDS)
Phase 2 enrolment to be completed summer of 2020.
ME-401
Relapsed/refractory Follicular Lymphoma (FL) Non Hodgkin Lymphoma
Phase 1 final data presented at ASCO June 1, 2019 noted statistically significant biologic anti-tumor activity.
ME-344
HER2-negative Breast Cancer
Phase 3 ongoing.
Pracinostat in combination with Vidaza
Acute Myeloid Leukemia
Phase 1 update due 2020.
Voruciclib
B-Cell Malignancies
Phase 1b updated data presented at ASCO May 29, 2020.
ME-401
Relapsed/refractory Follicular Lymphoma/Chronic Lymphocytic Leukemia (CLL)

Latest News

  1. MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program

    SAN DIEGO, May 26, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will host an investor and

  2. MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress

    SAN DIEGO and TOKYO, May 14, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a

  3. Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes

    LUGANO, Switzerland and SAN DIEGO, May 13, 2020 /PRNewswire/ -- Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, and MEI Pharma, Inc. (NASDAQ:MEIP), a

  4. MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b Study Evaluating ME-401 on an Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies; Data to be Featured in the American Society of Clinical Oncology 2020 Virtual Scientific Program

    SAN DIEGO and TOKYO, May 13, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:

  5. MEI Pharma Reports Fiscal Third-Quarter 2020 Results and Recent Corporate Highlights

    SAN DIEGO, May 7, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its third quarter ended

  6. MEI Pharma to Present at the 19th Annual Needham Virtual Healthcare Conference

  7. MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma

    SAN DIEGO, March 31, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the U.S. Food and Drug

  8. MEI Pharma Reports Fiscal Second-Quarter 2020 Results and Operational Highlights

    SAN DIEGO, Feb. 6, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its second quarter

  9. MEI Pharma Announces Closing of Public Offering of Common Stock

    SAN DIEGO, Dec. 19, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it has closed the underwritten public

  10. MEI Pharma Announces Pricing of Public Offering of Common Stock

    SAN DIEGO, Dec. 17, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it has priced the underwritten public

  11. MEI Pharma Announces Proposed Public Offering of Common Stock

    SAN DIEGO, Dec. 16, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it plans to offer shares of its common

  12. MEI Pharma to Present at the Stifel 2019 Healthcare Conference

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late‐stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief

  13. MEI Pharma Reports First Quarter Fiscal Year 2020 Results and Operational Highlights

    SAN DIEGO, Nov. 7, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its first quarter ended September 30,

  14. MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies

    SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced updated data from the ongoing Phase 1b

  15. MEI Pharma to Host Investor and Analyst Event on October 4, 2019

    SAN DIEGO, Sept. 23, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will host an investor and analyst event

  16. MEI Pharma to Present at the 2019 Wells Fargo Healthcare Conference

    SAN DIEGO, Aug. 29, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late‐stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief

  17. MEI Pharma Reports Fiscal Year 2019 Results and Operational Highlights

    SAN DIEGO, Aug. 28, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30,